



Business Results First Nine Months of the Fiscal Year Ending March 31, 2026

Sysmex Corporation
February 12, 2026

**Together for a better
healthcare journey**

Disclaimer

- This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.
- The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained.
- The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.

Index

- 1. Executive Summary**
- 2. Business Results, First Nine Months of the Fiscal Year Ending March 31, 2026**
- 3. Growth Strategy Progress**
- 4. Financial Forecast for the Fiscal Year Ending March 31, 2026**
- 5. Looking Ahead to the Next Mid-Term Management Plan**

(Appendix)

1. Executive Summary

Executive Summary



Results for the First Nine Months of the Fiscal Year Ending March 31, 2026

- **Despite favorable results in the Americas and EMEA, sales and profits were down, due to on going changes in the Chinese market environment.**

Year on year, net sales were down 1.6%, operating profit was down 27.7%, and profit attributable to owners of the parent was down 20.9%.

Net sales

- Sales grew in the Americas and EMEA, mainly on the hematology and urinalysis fields.
- In China, the effects of government-driven healthcare cost control policies persisted. Sales in China declined 19.0% year on year on a local currency basis due to the principle of minimal necessity (restrictions on set tests) and Inventory adjustments by distributors.

Operating profit

- Although SG&A expenses optimized, operating profit declined, affected, additional U.S. tariffs, and a decrease in gross profit on lower sales.

Profit attributable to owners of the parent

- In line with expectations (progress rate: 74.9%), reflecting foreign exchange impacts and tax effects associated with the liquidation of an affiliated company according to the Life science Business-Pivot.

Executive Summary



Financial Forecast for the Fiscal Year Ending March 31, 2026

Note : Figures in parentheses indicate the difference from the forecast disclosed in November.

- **We have revised downwards our forecast for net sales to ¥500.0 billion (-¥10.0 billion), and for operating profit to ¥62.0 billion (- ¥14.0 billion).**

Net sales

- Revised downward, reflecting the greater-than-expected impact of market environment changes in China, the revision of the medical robotics business plan in Japan, and conditions in other regions.

Operating profit

- Revised downward, reflecting lower gross profit resulting from reduced sales, as well as a deterioration in the cost ratio driven by factors such as product mix.

2.


**Business Results, First Nine Months of the
Fiscal Year Ending March 31, 2026**

Financial Highlights (Year on Year)



(Billions of yen)	First nine months of fiscal year ending March 31, 2026		First nine months of fiscal year ended March 31, 2025		YoY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net sales	361.1	100%	366.8	100%	98.4%
Cost of sales	173.5	48.0%	168.0	45.8%	103.3%
SG&A expenses	120.2	33.3%	109.9	30.0%	109.3%
R&D expenses	20.4	5.7%	22.5	6.1%	90.7%
Other income (expenses)	1.6	0.5%	1.0	0.3%	159.8%
Operating profit	48.6	13.5%	67.3	18.4%	72.3%
Profit attributable to owners of the parent	33.6	9.3%	42.6	11.6%	79.1%


- **Net sales:** Sales decreased, mainly due to the impact of changes in the market environment in China.
- **Operating profit:** Profit declined, reflecting lower gross profit resulting from the decrease in sales, as well as the impact of additional U.S. tariffs.
 - ✓ **Forex impact:** Sales: -¥0.09 billion, SG&A expenses: +¥0.50 billion, operating profit: -¥2.68 billion
 - ✓ **At the rates prevailing one year earlier:** Sales down 1.5%, SG&A expenses up 8.9%, operating profit down 23.8%
- **Profit attributable to owners of the parent:** Despite profit fell 20.9%, results were generally in line with the plan (progress rate: 74.9%)
 - ✓ **Foreign exchange gain (loss):** ¥2.01 billion (+¥4.41 billion year on year)
 - ✓ **Tax adjustment effects related to the liquidation of affiliated company according to the Life science Business-Pivot:** +¥2.58 billion



	First nine months of fiscal year ending March 31, 2026	First nine months of fiscal year ended March 31, 2025
1USD	¥148.7	¥152.6
1EUR	¥171.8	¥164.8
1CNY	¥20.8	¥21.2

Breakdown of Net Sales (by Business and Field)

Sales by Business and Field



(Billions of yen)	First nine months of fiscal year ending March 31, 2026		YoY (Previous period = 100%)	
	Results	Ratio	Yen basis	Excluding FX impact
Net sales	361.1	100.0%	98.4%	98.5%
Hematology	216.9	60.1%	98.1%	98.2%
FCM	2.9	0.8%	123.5%	122.3%
Urinalysis	32.0	8.9%	106.0%	106.5%
Hemostasis	53.7	14.9%	93.9%	94.2%
Immunochemistry	15.9	4.4%	86.9%	88.0%
Clinical chemistry	2.1	0.6%	80.4%	81.6%
Life science	17.0	4.7%	106.9%	103.8%
Others	18.0	5.0%	116.0%	113.9%
Diagnostics business	358.8	99.4%	98.7%	98.7%
Medical robotics business	2.3	0.6%	70.3%	70.3%

Breakdown of Net Sales (by Destination and Product Type)

Net sales were down, owing to the impact of performance in Japan and China, although sales rose firmly in the Americas, EMEA, and AP.

(Billions of yen)	First nine months of fiscal year ending March 31, 2026		YoY (Previous period = 100%)	
	Results	Ratio	Yen basis	Local currency basis
Net sales	361.1	100.0%	98.4%	98.5%*
Americas	100.8	27.9%	104.6%	107.1%
EMEA	114.9	31.8%	111.7%	107.0%
China	65.5	18.2%	79.9%	81.0%
AP	39.3	10.9%	102.6%	104.1%*
Japan	40.5	11.2%	85.8%	-
Instruments	70.5	19.5%	99.0%	98.5%*
Reagents	225.8	62.5%	98.6%	98.7%*
Services	50.9	14.1%	100.8%	101.4%*
Others	13.8	3.8%	86.7%	85.7%*


*Year-on-year change on a yen basis, excluding the impact of exchange rate fluctuations

Major Reasons for Changes by Destination Note: On a local currency basis

Americas	<ul style="list-style-type: none"> Favorable performance in North America continued following 1H, strong growth in Central and Latin America continued from Q2 onward, resulting in higher sales overall. In Q3 alone, sales grew 9.4% year on year.
EMEA	<ul style="list-style-type: none"> Strong performance in hematology and urinalysis across major countries and Eastern Europe offset sales declines in the Middle East, resulting in higher sales overall. In Q3 alone, sales increased significantly by 12.6% year on year.
China	<ul style="list-style-type: none"> Sales declined due to the expanding impact of healthcare cost control policies (including the principle of minimal necessity), as well as expanded inventory adjustments driven by deteriorating distributor finances and cautious purchasing behavior.
AP	<ul style="list-style-type: none"> Despite the delay of large-scale tender projects in India, sales increased, supported by growth in other regions.
Japan	<ul style="list-style-type: none"> Sales decreased due to a reaction to strong hematology instrument sales in the previous fiscal year, as well as the continued impact of special factors.


By Destination

(Billions of yen)



By Product Type

(Billions of yen)



Information by Destination (Americas)

(Million USD)	First nine months of fiscal year ending March 31, 2026	First nine months of fiscal year ended March 31, 2025	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	677.2	632.3	107.1%	104.6%
Instruments	149.3	134.6	110.9%	108.4%
Reagents	339.5	321.8	105.5%	103.0%
Services, others	188.4	175.8	107.1%	104.6%


Favorable performance in North America continued following 1H, strong growth in Central and Latin America continued from Q2 onward, resulting in higher sales overall. In Q3 alone, sales grew 9.4% year on year.

● Instruments

- ✓ Installations progressed steadily, with favorable performance in the hematology and urinalysis fields, as well as growth in the hemostasis field.
- ✓ In particular, installations in large-scale facilities advanced in the urinalysis field, and we anticipate further growth.

● Reagents

- ✓ Reagent sales increased, reflecting steady performance in the hematology and urinalysis fields.
- ✓ Amyloid β test reagents continued to show solid performance (sales USD 6.1 million, up 24.9% year on year).
- ✓ In the hemostasis field, reagent sales are expected to increase going forward in line with higher instrument sales.



Information by Destination (EMEA)

(Million EUR)	First nine months of fiscal year ending March 31, 2026	First nine months of fiscal year ended March 31, 2025	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	667.9	624.1	107.0%	111.7%
Instruments	154.3	136.7	112.9%	118.1%
Reagents	412.7	390.2	105.8%	110.3%
Services, others	100.9	97.2	103.8%	108.4%


Sales increased due to strong performance in hematology and urinalysis across major countries and Eastern Europe, resulting in higher sales overall. In Q3 alone, sales increased significantly by 12.6% year on year.

● Instruments

- ✓ Supported by the effects of the direct sales structure, the hematology and urinalysis fields performed strongly in Italy.
- ✓ XR™-Series sales grew in countries such as the Czech Republic and Germany.
- ✓ In the hemostasis field, we won major tenders not only in Germany but also in Hungary and the Czech Republic, which are expected to contribute to future sales.

● Reagents

- ✓ Despite sales declines in Turkey and Saudi Arabia, performance in key countries remained solid, resulting in growth across all Business fields.
- ✓ In the hemostasis field, reagent sales increased in countries such as Germany and Egypt, in line with the expansion of the installed instrument base.



(First nine months of years to March 31)

Note: Sales in Russia have been excluded, including for past years.

Information by Destination (China)

(Million CNY)	First nine months of fiscal year ending March 31, 2026	First nine months of fiscal year ended March 31, 2025	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	3,150.7	3,888.6	81.0%	79.9%
Instruments	381.8	458.9	83.2%	82.4%
Reagents	2,444.3	2,920.4	83.7%	82.4%
Services, others	324.5	509.2	63.7%	63.1%


Sales declined due to the expanding impact of government-driven policies to control healthcare costs (principle of minimal necessity), as well as inventory adjustments associated with changes to primary distributors.

● Instruments


- ✓ Sales declined due to distributor inventory adjustments and other factors.
- ✓ Sales in the hemostasis field increased, with steady performance continuing from the second half of the previous fiscal year, supported by the impact of knockdown local production.

● Reagents

- ✓ Due to the expanded impact of the principle of minimal necessity, the decline in the number of tests—particularly in the hemostasis field—had a significant impact.
- ✓ There was no significant difference in the trend of hematology test volumes.




■ Hematology test volume trends in China
(Sysmex estimate)



Outlook for China

We expect the year-on-year decline to be most pronounced in Q4. From next fiscal year onward, the pace of decline should gradually ease, with performance remaining at a broadly flat level in 2H.

Illustration of the Impact of Changes in the China Market Environment on YoY Performance by Quarter



Current situation

- **The impact of the principle of minimal necessity**
 - The reduction range has increased, particularly in the field of hemostasis. (e.g., D-Dimer)
- **The impact of the inventory adjustment driven by distributors**
 - The impact is ongoing.

Outlook

Q4

- The impact of the principle of minimal necessity
 - The reduction range has increased, particularly in the field of hemostasis.
- The impact of the inventory adjustment driven by distributors
 - The reduction of instrument sales is within the expected range.
 - The sales of reagents and consumables decreased more than anticipated

Next fiscal year

- 1H : continue to be negatively impacted year-on-year basis.
- 2H: expected to remain at broadly flat level

Changes in the number of hospitals and patients in 2024

	Hospitals		Outpatients	
	Number	Change (VS. 2023)	Patients (100 million people)	Growth rate (VS. 2023)
Tier 3	4,111	+256	28.7	9.1%
Tier 2	12,294	+348	12.2	0%
Tier 1	13,287	+35	2.5	0%

Information by Destination (AP)

(Billions of yen)	First nine months of fiscal year ending March 31, 2026	First nine months of fiscal year ended March 31, 2025	YoY (Previous period = 100%) Yen basis
Net sales	39.3	38.3	102.6% (104.1%)
Diagnostics business	39.2	38.3	102.4%
Instruments	7.4	8.1	91.1%
Reagents	27.8	25.9	107.6%
Services, others	3.9	4.2	92.5%
Medical robotics business	0.1	0.03	336.1%

Note: Figures in parentheses exclude the impact of exchange rate fluctuations)

Despite the delay of large-scale tenders in India, sales increased, supported by growth in other countries.

Diagnostics business

● Instruments


- ✓ Sales declined due to lower sales in Indonesia, as well as the deferral of large tenders in India and other countries.
- ✓ A significant growth is expected driven by acquisition of large-scale tenders scheduled for Q4.

● Reagents

- ✓ In addition to significant growth in the hemostasis field in Malaysia, sales increased supported by favorable performance in the hematology, urinalysis, and immunochemistry fields.

Medical robotics business

- ✓ Total cumulative installations: four units.
- ✓ The number of surgeries continues to increase steadily, with more than 150 procedures performed in Singapore and Malaysia.



Information by Destination (Japan)

(Billions of yen)	First nine months of fiscal year ending March 31, 2026	First nine months of fiscal year ended March 31, 2025	YoY (Previous period = 100%) Yen basis
Net sales	40.5	47.1	85.8%
Diagnostics business	38.3	43.9	87.2%
Instruments	5.5	8.5	65.6%
Reagents	25.6	28.1	91.1%
Services, others	7.0	7.2	97.7%
Medical robotics business	2.1	3.2	67.4%

Sales decreased due to a reaction to strong hematology instrument sales in the previous fiscal year, as well as the continued impact of special factors.

Diagnostics business

● Instruments


- ✓ Instrument sales declined in reaction to strong performance in the hematology field in the previous fiscal year.
- ✓ We launched new products, including the CN™-700 in the hemostasis field and the HISCL™-5000 mid-scale change in the immunochemistry field

● Reagents


- ✓ Sales declined due to special factors in Q1, as well as to a decrease in COVID-19 testing.
- ✓ We launched multiple immunochemistry reagents, which we expect to contribute to future sales.

Medical robotics business

- ✓ Although new installations declined year on year due to continued weak capital investment by hospitals, the cumulative installed base increased to 96 units in Japan (100 units globally).
- ✓ A total of ten units have been installed year to date in Japan (11 units globally).



Breakdown of Operating Profit (Year on Year)



Note: Figures and comments below exclude the impact of exchange rates.

- Fluctuation in gross profit due to changes in net sales: - ¥3.03 billion
 - Impact of change in the cost of sales ratio: - ¥5.95 billion (1.6pt deterioration)
 - ✓ Positive factor: Improved logistics costs, 0.1 pt
 - ✓ Negative factors: Impact of product mix, 0.5 pt; Q1 inventory revaluations, 0.5pt, deterioration of service costs, 0.5pt, tariff impact, 0.3 pt
 - Higher SG&A expenses: - ¥7.38 billion
 - ✓ Labor costs rose approx. ¥3.1 billion, due to personnel increases owing to expansion of the direct sales area, as well as higher unit costs.
 - ✓ Other costs rose approx. ¥2.5 billion in line with an increase in scale and sales promotion activities.
 - Higher depreciation and amortization: - ¥2.35 billion
 - Lower R&D expenses: + ¥2.09 billion
 - ✓ While investment in product development continues, total R&D expenses declined due to prioritization and narrowing of research themes.
 - Change in other operating expenses: ¥0.62 billion
-
- FX impact: -¥2.68 billion

3. **Growth Strategy Progress**

Reinforcement of Existing Businesses,
Emerging Market Strategies,
Expansion of New Businesses

Three Growth Strategies: Reinforcement of Existing Businesses (Hemostasis Field)

We are leveraging our strong foundation in hematology and the launch of new products to expand the value we deliver, driving higher customer satisfaction and accelerated growth.

- **Accelerate market expansion by leveraging brand strength**

EMEA: Winning of large tenders in Germany and other countries




CN-Series automated blood coagulation analyzer



- Key countries with major new tender wins

- **Bolster our presence in the high-end market**

- ✓ Rollout of the touch-free concept in the hemostasis field



CN-9000 automated hemostasis solution

North America: Launched the CN-9000

- **Expand our competitive advantage in mid- and low-end markets**

- ✓ Compactly incorporate the performance of higher-end models
- ✓ Consider introduction in emerging markets



CN-700 automated blood coagulation analyzer


Japan: Launched the CN-700

Three Growth Strategies: Reinforcement of Existing Businesses (Immunochemistry Field)

We aim to increase growth by enhancing our presence and market penetration in Alzheimer's disease testing.

- **Presentation of MTBR-tau243 at international conferences**

- ✓ World's first presentation of an immunoassay using blood samples
- ✓ Strong expectations from drug discovery partners developing tau disease-modifying therapies




In addition to anti-amyloid disease-modifying drugs, we are advancing the development of blood tests in anticipation of the arrival of anti-tau disease therapeutics.

- **Enhance market leadership through early market entry**

Began sales collaboration with Fujirebio HD




- ✓ Fujirebio HD's extensive product lineup
- ✓ Sysmex's global sales network
- ✓ Stronger collaboration with KOLs and participation in development of guidelines



Target countries/areas: Begin with Brazil, Central and Latin America, the Middle East, and Asia

In addition to rolling out the HISCL series in advanced markets, we are pursuing global expansion.

Three Growth Strategies: Emerging Market Strategy



*META : Middle East, Turkey, and Africa

Leverage our competitive advantage in emerging markets

- **India: Advancing initiatives to address government procurement tenders**

- ✓ Achieved Make in India Class I at a new production facility, and additionally obtained IVDD CE marking under European regulations.



XQ™-320 multiparameter automated hematology analyzer for the Indian market

- **Brazil: Long-standing trust grounded in high-customer satisfaction**

- ✓ Successfully retained business at a large commercial lab in Brazil, overcoming competitors' low-price strategies.

- **Malaysia: Proposing solutions to laboratory-wide challenges beyond instrument replacement**

- ✓ Our solutions were adopted by a reference laboratory positioned as a top-priority customer by competitors.



XR-Series multiparameter automated hematology analyzer

Secured multiple-system installations for the XR-Series




Three Growth Strategies: Expansion of New Businesses (Medical Robotics Business)




Accelerating market penetration and growth in case volumes,
with cumulative installations surpassing 100 units

- ✓ Japan: We are targeting further market penetration by introducing flexible sales schemes and benefiting from tailwinds, such as subsidies under programs aimed at enhancing functionality of university hospitals.
- ✓ AP: Against the backdrop of increasing case volumes in the expanding Asian market, we are advancing the selection of future entry countries and the development of market introduction frameworks.
- ✓ Europe: Assuming we receive regulatory approval, we will move forward with efforts to develop optimal market entry models.

hinotori™ units installed to date globally



hinotori™ surgeries performed to date globally



4. Financial Forecast for the Fiscal Year Ending March 31, 2026

Revised Financial Forecast for the Fiscal Year Ending March 31, 2026



Green indicates changes from previous forecast (announced in November 2025)

Revision of Net Sales, Operating Profit, and Net Income Forecasts Downward

(Billions of yen)	Q3 of Fiscal year ending March 31, 2026 (April–December)			Fiscal year ending March 31, 2026 (April–March)		Fiscal year ending March 31, 2026 (April–March)			
	Results	Ratio	Vs. November Revised forecast	November forecast	Ratio	Revised February Forecast	Ratio	YoY	Vs. November forecast
Net sales	361.1	100%	70.8%	510.0	100.0%	500.0	100.0%	98.3%	-10.0
Cost of sales	173.5	48.0%	-	241.5	47.4%	244.0	48.8%	103.1%	+2.5
SG&A expenses	120.2	33.3%	-	163.5	32.1%	165.0	33.0%	109.4%	+1.5
R&D expenses	20.4	5.7%	-	30.0	5.9%	30.0	6.0%	95.4%	—
Other income (expenses)	1.6	0.5%	-	1.0	-	1.0	0.2%	—	—
Operating profit	48.6	13.5%	64.0%	76.0	14.9%	62.0	12.4%	70.8%	-14.0
profit attributable to owners of the parent	33.6	9.3%	74.9%	45.0	8.8%	41.0	8.2%	76.4%	-4.0
Planned investment	Capital expenditure: ¥50.0 billion		Depreciation and amortization: ¥45.0 billion		ROE	8.5%			

● Assumed Exchange Rates

	Full year (Revised Nov. 2025)	Full year (Revised Feb 2026)	Q4 alone (Revised February 2026)
1 USD	¥148.5	¥150.0	¥154.0
1 EUR	¥171.5	¥174.6	¥183.0
1 CNY	¥20.8	¥21.1	¥22.0

● Exchange Rate Sensitivity (Q4 alone)

	Net Sales	Operating profit
USD	¥0.22 billion	¥0.03 billion
EUR	¥0.18 billion	¥0.01 billion
CNY*	¥0.09 billion	¥0.05 billion


*Per ¥0.1 change

Revised Financial Forecast for the Fiscal Year Ending March 31, 2026



Net sales


(Billions of yen)



- The impact of the principle of minimal necessity and distributor inventory adjustments in China was more extensive than we had anticipated.
- In Japan, we revised plans for the medical robotics business in response to a deteriorating business environment.

Operating profit

(Billions of yen)



- Gross profit declined due to lower sales across regions.
- The cost of sales ratio deteriorated due to product-mix etc.

Quarterly Results and Forecast for the Fiscal Year Ending March 31, 2026



(Billions of yen)	Q1 of fiscal year ending March 31, 2026 (April–June)		Q2 of fiscal year ending March 31, 2026 (July–September)		Q3 of fiscal year ending March 31, 2026 (October–December)		Q4 of fiscal year ending March 31, 2026 (January–March)	
	Results	Ratio	Results	Ratio	Results	Ratio	Forecast	Ratio
Net sales	105.7	100%	126.7	100%	128.6	100%	138.8	100%
Cost of sales	51.2	48.5%	58.7	46.3%	63.5	49.4%	70.4	50.8%
SG&A expenses	38.2	36.2%	39.5	31.2%	42.3	32.9%	44.7	32.3%
R&D expenses	6.4	6.1%	6.7	5.4%	7.2	5.6%	9.5	6.9%
Other income (expenses)	0.8	0.8%	0.6	0.5%	0.1	0.2%	-0.7	—
Operating profit	10.6	10.1%	22.3	17.6%	15.6	12.2%	13.3	9.6%
profit attributable to owners of the parent	4.5	4.3%	14.4	11.4%	14.8	11.5%	7.3	5.3%

Cost of Sales Ratio by Quarter, and Outlook for the Fiscal Year Ending March 31, 2026



Cost of sales ratio, by quarter
Fiscal year ended March 31, 2025

Q1	Q2	Q3	Q4
46.4%	45.4%	45.7%	48.4%

+2.5 pt: Exchange rate effects,
product mix, etc.

+0.7 pt: Changes in the China
business environment

+0.5 pt: Additional U.S. tariffs

Year on year
+ 3.7pt

Excluding the increase in reagent volume in
Japan due to the effects of system transition

49.0%

Product mix
(lower proportion of reagents)

Expanded impact of changes in
the China business environment

Additional U.S. tariffs

Cost of sales ratio by quarter
(actual/forecast)
Fiscal year ending March 31, 2026

Q1 (actual)	Q2 (actual)	Q3 (actual)	Q4 (forecast)
48.5%	46.3%	49.4%	50.8%

+2.0 pt: Exchange rate effects,
product mix, etc.

+0.8 pt: Changes in the China
business environment

+0.3 pt: Additional U.S. tariffs

vs. Q2
+ 3.1pt

Product mix
(lower proportion of reagents)

Increased impact of changes in
the China business environment

Factors that may continue to have an impact

Temporary factors/factors with potential for
improvement

Reference: Financial Forecast for the Fiscal Year Ending March 31, 2026 (Sales by Business, Field, and Destination)



Sales by business and field

(Billions of yen)

	Fy03/2026	YoY (Previous period = 100%)
Hematology	299.5	98.8%
FCM	5.0	137.4%
Urinalysis	46.5	113.9%
Hemostasis	72.0	87.4%
Immunochemistry	21.5	83.1%
Clinical chemistry	3.0	82.6%
Life science	24.5	114.9%
Others	24.5	109.3%
Diagnostics business	496.5	98.7%
Medical robotics business	3.5	65.2%
Total	500.0	98.3%

Sales by destination

(Billions of yen)

	Fy03/2026	YoY (Previous period = 100%)
Americas	139.0	106.0%
EMEA	161.5	115.0%
China	86.0	72.9%
Asia Pacific	55.5	108.1%
Japan	58.0	85.6%

Text in green indicates revisions.

5. Looking Ahead to the Next Mid-Term Management Plan

Key Points of the Next Medium-Term Management Plan



- **Commit to sustaining growth in existing businesses**
 - Global rollout of new flagship model with novel solution
- **Accelerate digital transformation leveraging Sysmex's strengths**
 - Challenge to develop solutions that enhance the quality of the healthcare journey and customer value.
 - Transform corporate efficiency and productivity to the next stage.
- **Manage the business with full consideration of geopolitical and economic security risks worldwide, including changes in the business environment in China etc.**
- **Strengthen management of the business portfolio and product pipeline with a focus on group-wide profitability**
- **Develop and acquire next-generation talent who will lead the next stage of growth**
- **Improve capital efficiency and enhance shareholder returns, including share buyback**

(Appendix)

Highlights (October 2025 to January 2026)



Diagnostics Business

Launched new products in multiple fields

- Launch of CN-9000 Automated Hemostasis Solution for Large-Scale Laboratories in North America (Americas)
- Introduction of Compact Model to the CN-Series: Launch of the CN-700 Automated Blood Coagulation Analyzer (Japan)
- Launch of HISCL -5000 Fully Automated Immunoassay System (Mid-Scale Change) (Japan)
- Launch of the HISCL™ PCT Reagent for Measuring Procalcitonin, a Biomarker Used in Sepsis Testing (Japan)

Sustainability

Strengthened the business foundation to enhance sustainable growth capabilities

- Sysmex Selected for CDP 2025 “Climate Change” A List
- Sysmex Obtains “Platinum Kurumin Plus,” the Highest Level of Certification under the “Kurumin” Program Provided by the Ministry of Health, Labour and Welfare, Based on the Act on Advancement of Measures to Support Raising Next-Generation Children
- Sysmex Receives the Highest Rating of GOLD in the “Pride Index” for Its Efforts Related to Sexual and Gender Minorities, for the Fourth Consecutive Year



Together for a better
healthcare journey